Symptoms of peripheral arterial disease: ramipril

£1.33 for 28. Ramipril 2.5 mg/5 ml oral solution costs £96.00 for 150 ml (Drug Tariff, October 2015). Evidence review This evidence summary discusses 2 randomised controlled trials (RCTs) that evaluated ramipril for treating intermittent claudication in people with peripheral arterial disease. A third RCT (Ahimastos et al. 2013, n=212) was originally included in this evidence summary but has now been removed. This follows a statement published in the Journal of the American Medical Association (JAMA), which advised that the RCT has been retracted after the lead author, Anna Ahimastos, admitted to fabricating the results of this and a related study. This author was also the lead author for another RCT included in this evidence summary and it is unclear whether the integrity of that study is also affected. However, because of the paucity of evidence, the decision has been taken to present the results, with the proviso that the data may not be robust. The results of a meta-analysis by Shahin et al. (2013b) have also been removed from the evidence summary because they were primarily based on the RCT by Ahimastos et al. (2013). However, some background data on the studies that are still included was obtained from
